Allergan’s failed depression drug shows promise in opioid withdrawal

Allergan's rapastinel, the centerpiece of its $560 million acquisition of Naurex, recently failed in pivotal trials in depression. But scientists at Duke University and Villanova University may have found another use for the drug—to aid in opioid withdrawal.